

EMJ

European Medical Journal

Volume 14 Supplement 1
March 2026
emjreviews.com

Poster Review

Real-World Analysis of
the ImmunoWELL JCV
Test in Natalizumab
Progressive Multifocal
Leukoencephalopathy
Risk Monitoring



Neurology
Supplement



Real-World Analysis of the ImmunoWELL JCV Test in Natalizumab ▼ Progressive Multifocal Leukoencephalopathy Risk Monitoring

Data from a poster presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Congress held in Barcelona, Spain, from 24th–26th September 2025

Support: The publication of this article was funded by Sandoz. This article is intended only for the HCPs in countries where ImmunoWELL JCV test is available for testing.

Presenter: Altaher Esmael¹
1. Hexal AG (a Sandoz company), Holzkirchen, Germany

Disclosure: Esmael is an employee of Hexal AG (a Sandoz company).

Acknowledgements: Writing assistance was provided by Helen Boreham, HB Medical (UK) Ltd, Wetherby, UK.

Disclaimer: The poster presentation on which this article is based is not intended for HCPs from the USA.

Prescribing information for Tyruko ▼ (natalizumab) can be found [here](#). Always consult local prescribing information in country of practice as information may vary. ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Details on adverse event reporting are given at the end of this article.

Keywords: Anti-JCV antibodies, ImmunoWELL JCV test, John Cunningham virus (JCV), multiple sclerosis (MS), natalizumab, progressive multifocal leukoencephalopathy (PML), real-world data, risk stratification.

Citation: EMJ Neurol. 2026;14[Suppl 2]:2-6.
<https://doi.org/10.33590/emjneuro/V3S5B28Y>



Meeting Summary

The presence of antibodies to John Cunningham virus (JCV) represents one of the three established factors used to estimate the risk of progressive multifocal leukoencephalopathy (PML), a serious and potentially fatal brain infection associated with natalizumab treatment. ImmunoWELL JCV (Sandoz AG, Basel, Switzerland) is a validated, two-step assay that qualitatively detects anti-JCV antibodies in human serum and supports PML risk stratification in patients with multiple sclerosis (MS) receiving or considering natalizumab. A recent e-poster presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona, Spain, reported the first real-world data on European use of the ImmunoWELL JCV test

for PML risk monitoring in patients with MS initiating or receiving natalizumab. Results from this multinational analysis of the ImmunoWELL JCV test in Europe support its clinical utility as a reliable tool for anti-JCV antibody assessment and monitoring.

Introduction

JCV is a DNA polyomavirus and the primary aetiological agent of PML.^{1,2} Most adults carry JCV in its latent form, but the virus can become reactivated during treatment with immunosuppressive monoclonal antibodies such as natalizumab.^{1,2} Serum anti-JCV antibody testing is recommended prior to initiating natalizumab therapy, with retesting every 6 months due to considerations such as new infection or fluctuating antibody levels.^{3,4}

The ImmunoWELL JCV test is currently used in the clinical practice setting in Europe to support PML risk stratification in patients with MS receiving or considering natalizumab.⁵⁻⁷ This test is a validated, two-step, enzyme-linked, immunosorbent assay that qualitatively detects anti-JCV antibodies in human serum.⁵⁻⁷ It utilises a screening assay that measures antibody-antigen binding with peroxidase-conjugated anti-human IgG antibodies and categorises the sample as anti-JCV antibody 'positive', 'negative', or 'indeterminate'. If the sample reports an indeterminate result, a confirmation test on the same sample (second step) is required.⁷

European Real-World Analysis of the ImmunoWELL JCV Test

Esmael et al.⁸ conducted the first European real-world analysis of the ImmunoWELL JCV test for PML risk monitoring. In this study, aggregated ImmunoWELL JCV test data from April 2024–April 2025 were retrospectively analysed across eight European countries: France, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and the UK. Testing was performed by Medicover Integrated Clinical Services (MICS; Gdańsk, Poland) and its affiliated laboratory in Bucharest, Romania.⁸

Samples were categorised as 'new' or 're-tests' based on prior anti-JCV antibody testing history. Analyses included the monthly distribution of ImmunoWELL JCV test volumes, anti-JCV antibody status using qualitative assessment based on index values (≤ 0.20 negative and > 0.50 positive), and PML risk stratification based on the following index threshold values: low ≤ 0.8 , moderate > 0.8 – ≤ 1.4 , and high > 1.4 .⁸

ImmunoWELL JCV Test Data

A total of 16,763 test results were analysed between April 2024–2025, comprising 77.3% (12,965/16,763) new and 22.7% (3,798/16,763) re-tests. Of the total number of tests, 39.1% (6,550/16,763) were anti-JCV antibody-negative, and 60.9% (10,213/16,763) were anti-JCV antibody-positive (Figure 1).⁸


When considering the distribution of samples across PML risk index categories (low, moderate, high), most results fell into the low-risk category. The overall test distribution for low (index: ≤ 0.8), moderate (index: > 0.8 – ≤ 1.4), and high (index: > 1.4) PML risk was 79.7% (13,360/16,763), 7.4% (1,245/16,763), and 12.9% (2,158/16,763), respectively. Norway reported the highest percentage of tests in the low PML risk category (88.2%), whereas the UK recorded the highest percentage in the high PML risk category (19.5%; Figure 2).⁸

The 'low PML risk' category includes all test results with an index value of ≤ 0.8 , regardless of antibody status. Further analysis of the distribution of anti-JCV antibody-positive and -negative samples in the low PML risk category was therefore carried out.

Overall, 47.7% (6,373/13,360) of samples within this category were anti-JCV antibody-positive, while 52.3% (6,987/13,360) were anti-JCV antibody-negative (Figure 3).⁸

The observation that nearly half of the samples within the low risk group were positive for anti-JCV antibodies further supports the high sensitivity of the ImmunoWELL JCV assay.⁹

Figure 1: Percentage distribution of anti-JCV antibody-positive and -negative samples normalised by country (N=16,763).⁸



JCV: John Cunningham virus.

Figure 2: Percentage distribution of samples across progressive multifocal leukoencephalopathy risk index categories (low, moderate, high) normalised by country (N=16,763).⁸





Figure 3: Percentage distribution of anti-JCV antibody-positive and -negative samples in the low progressive multifocal leukoencephalopathy risk category (index ≤ 0.8), normalised by country (N=13,360).⁸



JCV: John Cunningham virus.

Conclusion

Evaluation of the distribution of anti-JCV antibody index values obtained using the ImmunoWELL JCV test, with over 16,700 results collected from eight countries over the course of 1 year, found that approximately 80% fell within the low PML risk category (≤ 0.8).⁸ This indicates a predominance of low-risk profiles among tested individuals, as well as a consistent pattern of results across different European

countries. Importantly, the overall percentage reported for low PML risk using the ImmunoWELL JCV test was broadly consistent with current known practices in clinical risk assessment and treatment decision-making.¹⁰

In summary, this first multinational, real-world analysis of the ImmunoWELL JCV test supports its clinical utility as a reliable tool for anti-JCV antibody assessment and monitoring in patients with MS receiving or considering treatment with natalizumab.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Sandoz on <https://www.sandoz.uk.com/about-us/contact-us/adverse-event-reporting/> or via email at adverse.event.uk@sandoz.com.

References

1. Bellizzi A et al. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. *Clin Dev Immunol*. 2013;2013:839719.
2. Pietropaolo V et al. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. *New Microbiol*. 2018;41(3):179-86.
3. European Medicines Agency (EMA). Tyruko (natalizumab). Summary of product characteristics. 2025. Available at: https://www.ema.europa.eu/en/documents/product-information/tyruko-epar-product-information_en.pdf. Last accessed: 5 January 2025.

4. European Medicines Agency (EMA). Tysabri (natalizumab). Summary of product characteristics. 2025. Available at: https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf. Last accessed: 5 January 2025.
5. Sandoz. ImmunoWELL™ JCV IgG test data summary. Available at: <https://www.my-sandoz.com/nl-nl/wsi-product/immunowelltm-jcv-igg-test-data-summary/>. Last accessed: 18 February 2026.
6. European Medicines Agency (EMA). Tyruko assessment report. 2023. Available at: https://www.ema.europa.eu/en/documents/assessment-report/tyruko-epar-public-assessment-report_en.pdf. Last accessed: 5 January 2025.
7. Adler F et al. A new assay for detection of anti-JCV antibodies to support risk stratification and monitoring for progressive multifocal leukoencephalopathy in patients considering or in treatment with natalizumab. Poster P1836.ECTRIMS, 18-20 September, 2024.
8. Esmael A et al. First-year multinational cohort data of the ImmunoWELL JCV test in natalizumab PML risk monitoring: descriptive analysis. Poster P2012.ECTRIMS, 24-26 September, 2025.
9. Esmael A et al. First-year multinational cohort data of the ImmunoWELL JCV test in natalizumab PML risk monitoring: descriptive analysis. Oral presentation DGN-IN-130. DGN-Kongress, 12-15 November, 2025.
10. Ryerson LZ et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. *Neurology*. 2019;93(15):e1452-62.